MOSCOW, RUSSIA - May, 2006 - ASINEX Ltd, a worldwide leader in lead generation and lead optimization, announced today that Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), Division of Janssen Pharmaceutica N.V., has renewed its discovery chemistry collaboration with ASINEX. ASINEX has provided a range of chemistry services to J&JPRD since 2002 that includes the synthesis of exclusive libraries, lead optimization and custom synthesis.

Dr. Dmitry Genis, CEO at ASINEX commented, "We are delighted that J&JPRD has agreed to continue its collaboration with ASINEX for another year. We enjoy the challenging projects we share with J&JPRD, ranging from the synthesis of exclusive libraries to complex optimization programs."

For additional information, please contact:

ASINEX Ltd

Alistair Melvin,
Head of Business Development
Phone: +7 095 780 3417
Email:

About ASINEX

Asinex (www.asinex.com) is a provider of 'Intelligent Chemistry' for lead generation and optimization. ASINEX is an innovative creator of novel high quality compound libraries for screening, and has more than 400,000 drug-like small molecules. The company has a total of 151 chemists (54 Ph.D.), 9 computational chemists (7 Ph.D.) and 38 biologists / biochemists (24 Ph.D.).